• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Complete Genomics sets price for IPO a nose ahead of Pacific Biosciences offering

Complete Genomics sets price for IPO a nose ahead of Pacific Biosciences offering

October 27, 2010 By MassDevice staff

GNOM, PACB logos

Complete Genomics Inc. yesterday filed for an initial public offering that could be worth up to $96.6 million, and if the popularity of a competing genome sequencing company’s stock is an indicator for its success, Complete Genomics won’t have much trouble hitting its mark.

Pacific Biosciences of California Inc. (NSDQ:PACB) entered the market today and raised $200 million in its IPO. The company is working on a whole-genome sequencing device that would deliver "real-time" observation of DNA-related processes.

The $16-per-share offering brings the total amount of money it’s raised since the Menlo Park, Calif.-based genomics firm‘s 2004 founding to $570 million, according to FierceBiotech.

In its IPO, Complete Genomics plans to offer 6 million shares at a range of $12 to $14 per share, according to a federal Securities & Exchange Commission filing.

The Mountain View, Calif.-based company is slated to set the actual IPO price the week of Nov. 8, according to Renaissance Capital, and requested the ticker symbol GNOM. The company was founded in 2005 and reported $2 million in revenue for the 12 months ending June 30. It’s working on another genome sequencing and analysis platform.

The genome sequencing market is expected to grow from $1.2 billion in 2009 to more than $3.6 billion by 2014, according to Scientia Advisors, which Pacific Biosciences cited in its IPO filing.

Healthcare IT, in addition to the pharmaceutical industry, are already heading in the direction of biomarker-based medicine, Scientia Advisors managing partner Harry Glorikian told MassDevice at Harvard Medical School’s World Health Forum in Boston in October. If a patient has positive or negative results for a particular test, there are already alarms built into healthcare IT applications that warn doctors about how certain treatments could affect the patient, said Glorikian.

“If that’s not directing the practice of medicine, I don’t know what is,” he said. “It’s supposed to be a guideline. It’s not etched in stone, but if you do something that it says you shouldn’t, ‘What was you medical rational for doing that?'” he asked.

The race to bring the cost of complete genome sequencing down has grown more and more competitive over the last couple months. Earlier this week, Helicos Biosciences Corp. (NSDQ:HLCS) amended its genome sequencing technology patent infringement lawsuit against Pacific Biosciences to include Life Technologies Corp. (NSDQ:LIFE) and Illumina Inc. (NSDQ:ILMN), two other companies trying to position themselves for the predicted exponential growth of DNA sequencing industry.

PACB shares were trading at $16.57 in midday activity.

Filed Under: Diagnostics, Genomics/Molecular Diagnostics Tagged With: Complete Genomics Inc., Pacific Biosciences Inc.

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy